ClinicalTrials.gg
CompletedNCT03019198Updated Mar 9, 2017

TRANEXAMIC ACID IN PATIENTS UNDERGOING TOTAL HIP ARTHROPLASTY IN A BRAZILIAN REFERENCE ORTHOPEDIC CENTER: A RANDOMIZED CONTROLLED TRIAL

A Phase 4 interventional study of Tranexamic Acid Injectable Solution and Placebo - Concentrate in Blood Loss, Surgical, Tranexamic Acid Adverse Reaction and Hip Replacement, sponsored by Instituto Nacional de Traumatologia e Ortopedia. Completed at 1 site in Brazil. Per ClinicalTrials.gov, last updated 2017-03-09.

Sponsored by Instituto Nacional de Traumatologia e Ortopedia · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
256
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing Tranexamic Acid in Blood Loss, Surgical — 9 open to participants now, 9 under way, 4 of them phase 3. Tranexamic Acid · Blood Loss, Surgical.

Enrollment
3rd of 46
256 · median 98
Started
2013
with 2 others
Phase 4
18 of 46
1 open now
Registered
12th of 46
by date

Among the 46 studies testing Tranexamic Acid in Blood Loss, Surgical, this one is the 3rd largest by enrollment, is one of 3 that started in 2013, is one of 18 in phase 4, and was the 12th registered.

Blood Loss, Surgical

213 studies on the registry are indexed under Blood Loss, Surgical; 40 are open to participants now.

Browse Blood Loss, Surgical studies →

Open to participants now

9 of the 46 studies testing Tranexamic Acid in Blood Loss, Surgical are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 27 Blood Loss, Surgical studies recruiting now, 10 (37%) set no upper age limit and 14 (52%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing Tranexamic Acid in Blood Loss, Surgical, or all of them as a file.
02

Study summary

This study aims to analyze the efficacy of intravenous tranexamic acid (TXA) in patients undergoing total hip arthroplasty (THA).

Read the detailed description

This was a prospective, experimental, randomized, controlled study of 308 consecutive patients who underwent primary THA from December 2013 to March 2014. 256 volunteers remained in the study, 128 were treated 15 mg/kg intravenous bolus of TXA and 128 did not receive the medication. Participants were followed up at 3 weeks, 3 months, 6 months, 1 year, and then annually after surgery.

The use of TXA resulted in lesser reduction in hemoglobin and hematocrit levels, reduced blood loss, blood transfusion rate, volume of blood products, and stay length even in risk factor patients.

TXA protects risk factor patients against intra and postoperative bleeding and reduces transfusion rates.

03

Conditions studied

  • Blood Loss, Surgical
  • Tranexamic Acid Adverse Reaction
  • Hip Replacement

Keywords

  • Tranexamic Acid
  • Blood loss
  • Tranfusion
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consecutive patients who need total hip replacement were included in the initial sample. There was no age limit or restriction regarding gender for admission to the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who underwent previous surgery in the same joint, evidence of joint infection, congenital or acquired coagulopathies, active intravascular coagulation, acute occlusive vasculopathy, to TXA, chronic use of oral and anticoagulants, history of severe or moderate allergy to plasma transfusion, chronic heart disease, malignant neoplasms and diseases, patients who needed bone graft or underwent hip arthroplasty revision surgeries, and who did not consent to participate in the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    TXA

    Performed an intravenous bolus administration of 15 mg/kg of TXA to the volunteers after the end of the anesthesia and 15 minutes prior to skin incision.

    Drug: Tranexamic Acid Injectable Solution

  • Placebo comparator
    Control

    This group underwent the same procedures of the TXA group, excepting the preoperative administration of the medication.

    Drug: Placebo - Concentrate

Interventions

06

What researchers measure

Primary outcomes

  1. Hemoglobin drop

    Time frame: 24 hours post operative

  2. Hematocrit drop

    Time frame: 24 hours post operative

  3. Blood transfusion rate

    Time frame: 5 days

  4. Operative blood loss

    Time frame: 24 hours post operative

Secondary outcomes

  1. Length of stay in hospital

    Time frame: 7 days

  2. Systemic adverse events

    Time frame: 1 year

  3. Thromboembolic efects

    Time frame: 1 year

07

Study locations

1 site
  • Instituto Nacional de Traumatologia e Ortopedia
    Rio de Janeiro, 20940070, Brazil
08

References and documents

Publications

  • Kimura OS, Freitas EH, Duarte ME, Cavalcanti AS, Fernandes MB. Tranexamic acid use in high-risk blood transfusion patients undergoing total hip replacement: a randomised controlled trial. Hip Int. 2021 Jul;31(4):456-464. doi: 10.1177/1120700019889947. Epub 2019 Dec 9. PubMed 31814452 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Mar 2014 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2017
First posted
Jan 12, 2017
Start
Dec 2013
Primary completionActual
Mar 2014
CompletionActual
Mar 2016
Last update
Mar 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03019198
Lead sponsor
Instituto Nacional de Traumatologia e Ortopedia
Responsible party
Osamu de Sandes Kimura (M.D., Instituto Nacional de Traumatologia e Ortopedia) — Principal investigator
First posted
Jan 12, 2017
Start date
Dec 2013
Primary completion
Mar 2014
Completion
Mar 2016
Last update
Mar 9, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion